GJA1 isoforms protect against metabolic stress
AssigneeCedars-Sinai Medical Center
InventorsRobin Shaw, TingTing Hong, Ying Fu, Shaohua Xiao, Wassim Basheer
Life of this patent
Estimating the term…
Abstract
The present invention describes methods of treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of a medical condition related to ischemia/reperfusion in a subject using GJA1-20k as a therapeutic agent. The invention further provides a method of protecting a cell from metabolic stress, using GJA1-20k. The invention also provides for a composition and/or gene expression vector comprising GJA1-20k.
Claims13
A method of treating, reducing the likelihood of having, reducing the severity of and/or slowing the progression of a condition in a subject, comprising:
- providing a polypeptide consisting of GJA1-20k polypeptide having SEQ ID NOs:
- 1, 2 or 3, or a polypeptide consisting of the GJA1-20k polypeptide having SEQ ID NOs:
- 1, 2 or 3 fused to a cell penetrating peptide (CPP), or a gene expression vector comprising a sequence encoding the polypeptide consisting of GJA1-20k polypeptide having SEQ ID NOs:
- 1, 2 or 3, wherein the gene expression vector is configured for expressing the polypeptide consisting of GJA1-20k polypeptide having SEQ ID NOs:
- 1, 2 or 3;
- and administering a therapeutically effective amount of the polypeptide consisting of GJA1-20k polypeptide having SEQ ID NOs:
- 1, 2 or 3, the polypeptide consisting of the GJA1-20k polypeptide having SEQ ID NOs:
- 1, 2 or 3 fused to a cell penetrating peptide (CPP), the gene expression vector comprising the sequence encoding the polypeptide consisting of GJA1-20k polypeptide having SEQ ID NOs:
- 1, 2 or 3, to the subject, thereby treating, reducing the likelihood of having, reducing the severity of and/or slowing the progression of the condition in the subject, wherein the condition is metabolic stress, ischemia, or both.
A method of protecting a cell from metabolic stress, comprising:
- providing
- a polypeptide consisting of GJA1-20k polypeptide having SEQ ID NOs:
- 1, 2 or 3, or
- a polypeptide consisting of the GJA1-20k polypeptide having SEQ ID NOs:
- 1, 2 or 3 fused to a cell penetrating peptide (CPP), or
- a gene expression vector comprising a sequence encoding the polypeptide consisting of GJA1-20k polypeptide having SEQ ID NOs:
- 1, 2 or 3, wherein the gene expression vector is configured for expressing the GJA1-20k polypeptide having SEQ ID NOs:1, 2 or 3;
- and contacting the cell with
- the polypeptide consisting of GJA1-20k polypeptide having SEQ ID NOs:
- 1, 2 or 3, or
- polypeptide consisting of the GJA1-20k polypeptide having SEQ ID NOs:
- 1, 2 or 3 fused to a cell penetrating peptide (CPP), or
- the gene expression vector comprising the sequence encoding the polypeptide consisting of GJA1-20k polypeptide having SEQ ID NOs:
- 1, 2 or 3, thereby protecting the cell from metabolic stress.
Dependencies are inferred from the claim text.